Literature DB >> 9090654

A typical hemolytic uremic syndrome in human immunodeficiency virus-1-infected children.

M E Turner1, K Kher, T Rakusan, L D'Angelo, S Kapur, D Selby, P E Ray.   

Abstract

We describe the clinical and pathological findings of the hemolytic uremic syndrome (HUS) in two children with human immunodeficiency virus (HIV) infection. Both patients presented with microangiopathic hemolytic anemia, thrombocytopenia, and subsequently developed renal failure. The diagnosis of HUS was confirmed by renal histopathology in both patients. None of these children presented with bloody diarrhea, evidence of circulating antibody response to Escherichia coli O157 lipopolysaccharide, or other known risk factors for HUS, except for the presence of HIV infection. Each patient was treated with intravenous plasma infusion and renal replacement therapy. Their clinical course was characterized by non-oliguria and lack of significant hypertension throughout the acute phase of the disease. Despite these favorable clinical parameters, both patients developed end-stage renal failure. The etiology of this atypical HUS characterized by poor renal survival remains unknown and the role of HIV infection in its pathogenesis, although possible, is unclear.

Entities:  

Mesh:

Year:  1997        PMID: 9090654     DOI: 10.1007/s004670050249

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  12 in total

1.  Atypical Hemolytic Uremic Syndrome in the Setting of Acute Clostridium difficile Colitis.

Authors:  Anshu Wadehra; Samer Alkassis
Journal:  Cureus       Date:  2021-02-09

Review 2.  Hypertension in the HIV-infected patient.

Authors:  S Aoun; E Ramos
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

3.  Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Gregory M Lucas; Michael J Ross; Peter G Stock; Michael G Shlipak; Christina M Wyatt; Samir K Gupta; Mohamed G Atta; Kara K Wools-Kaloustian; Paul A Pham; Leslie A Bruggeman; Jeffrey L Lennox; Patricio E Ray; Robert C Kalayjian
Journal:  Clin Infect Dis       Date:  2014-09-17       Impact factor: 9.079

4.  Hemolytic uremic syndrome associated with Entamoeba histolytica intestinal infection.

Authors:  Felipe Cavagnaro; Carla Guzmán; Paul Harris
Journal:  Pediatr Nephrol       Date:  2005-10-13       Impact factor: 3.714

Review 5.  Urinary biomarkers of kidney diseases in HIV-infected children.

Authors:  Sofia Perazzo; Ángel A Soler-García; Yetrib Hathout; Jharna R Das; Patricio E Ray
Journal:  Proteomics Clin Appl       Date:  2015-06       Impact factor: 3.494

6.  Iron-related proteins: candidate urine biomarkers in childhood HIV-associated renal diseases.

Authors:  Angel A Soler-García; Douglas Johnson; Yetrib Hathout; Patricio E Ray
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-11       Impact factor: 8.237

Review 7.  A 20-year history of childhood HIV-associated nephropathy.

Authors:  Patricio E Ray; Lian Xu; Tamara Rakusan; Xue-Hui Liu
Journal:  Pediatr Nephrol       Date:  2004-08-05       Impact factor: 3.714

Review 8.  Kidney disease in children and adolescents with perinatal HIV-1 infection.

Authors:  Rajendra Bhimma; Murli Udharam Purswani; Udai Kala
Journal:  J Int AIDS Soc       Date:  2013-06-18       Impact factor: 5.396

9.  Fusion of HIV-1 envelope-expressing cells to human glomerular endothelial cells through an CXCR4-mediated mechanism.

Authors:  Patricio E Ray; Angel A Soler-García; Lian Xu; Carl Soderland; Robert Blumenthal; Anu Puri
Journal:  Pediatr Nephrol       Date:  2005-07-27       Impact factor: 3.651

10.  Determining the prevalence of human immunodeficiency virus-associated nephropathy (HIVAN) using proteinuria and ultrasound findings in a Nigerian paediatric HIV population.

Authors:  Enobong Emmanuel Ikpeme; Udeme Ekpenyong Ekrikpo; Mkpouto Udeme Akpan; Samuel Itemobong Ekaidem
Journal:  Pan Afr Med J       Date:  2012-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.